Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MIST | US
0.02
1.07%
Healthcare
Biotechnology
30/06/2024
24/04/2026
1.89
1.93
1.94
1.86
Milestone Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil a novel and potent calcium channel blocker which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal Canada.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
72.9%1 month
118.2%3 months
94.0%6 months
84.5%-
-
2.48
1.67
0.60
-1.43
81.44
-
-49.19M
100.68M
100.68M
-
-
-
-100.00
-133.75
3.33
0.83
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.48
Range1M
1.34
Range3M
1.34
Rel. volume
0.25
Price X volume
1.31M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| IN8bio Inc. Common Stock | INAB | Biotechnology | 1.5 | 108.82M | 5.63% | n/a | 43.30% |
| Dermira Inc | DERM | Biotechnology | 5.15 | 106.75M | 0.39% | 47.08 | 201.92% |
| Common Stock | TARA | Biotechnology | 5.13 | 105.83M | -2.47% | n/a | 5.41% |
| Cellectar Biosciences Inc | CLRB | Biotechnology | 2.76 | 98.94M | -0.90% | n/a | 2.10% |
| NRXPW | NRXPW | Biotechnology | 0.0071 | 95.55M | 0.00% | n/a | -46.73% |
| Aldeyra Therapeutics Inc | ALDX | Biotechnology | 1.55 | 92.10M | -3.13% | n/a | 15.90% |
| Surrozen Inc. Common Stock | SRZN | Biotechnology | 28.14 | 90.21M | -8.14% | n/a | 35.73% |
| ALXO | ALXO | Biotechnology | 1.67 | 87.96M | 5.03% | n/a | 10.97% |
| Humacyte Inc | HUMA | Biotechnology | 0.7 | 87.73M | -1.14% | n/a | -63.37% |
| InflaRx N.V | IFRX | Biotechnology | 1.48 | 87.15M | -5.13% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 36.11 | 103.70M | 0.00% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.11 | 99.53M | 1.16% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.765 | 73.67M | 1.69% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.9 | 70.43M | 6.56% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.43 | 0.53 | Cheaper |
| Ent. to Revenue | 81.44 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.48 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 93.99 | 72.80 | Riskier |
| Debt to Equity | 1.67 | -1.23 | Expensive |
| Debt to Assets | 0.60 | 0.25 | Expensive |
| Market Cap | 100.68M | 3.66B | Emerging |